COVID-19 vaccines changed the course of the pandemic, dramatically reducing severe illness, hospitalization, and death. Yet SARS-CoV-2 continues to pull off an irritating party trick: entering through the nose, multiplying in the upper respiratory tract, and sometimes spreading before the immune system can fully respond.
That gap has fueled interest in a next-generation solutionthe nasal spray vaccine for SARS-CoV-2. Instead of delivering vaccine material into a muscle, an intranasal COVID vaccine aims to train immune defenses directly inside the nose and airways, where the virus usually begins its invasion.
The idea sounds wonderfully simple: spray, sniff, and let the immune system handle the uninvited microscopic guest. The underlying science, however, is anything but simple.
What Is a Nasal Spray Vaccine for SARS-CoV-2?
A nasal SARS-CoV-2 vaccine is administered into the nostrils rather than injected into the arm. Depending on the product, the spray may contain a weakened viral vector, an engineered protein, an inactivated virus, or another platform designed to show the immune system recognizable pieces of SARS-CoV-2.
The goal is not merely to create antibodies in the blood. Researchers want to build immunity in the mucosal tissues lining the nose, throat, and respiratory tract. These tissues form the virus’s usual front doorand SARS-CoV-2 has never shown much respect for a “No Soliciting” sign.
As of July 2026, the FDA’s list of licensed U.S. vaccines includes injectable mRNA and adjuvanted COVID-19 vaccines, but it does not include an approved intranasal SARS-CoV-2 vaccine. Several nasal candidates remain investigational in U.S. clinical development.
Why Scientists Want Immunity Inside the Nose
Systemic immunity and mucosal immunity are not identical
Vaccines injected into muscle are especially effective at generating systemic immune responses. They stimulate circulating antibodies, memory B cells, and T cells that can respond when an infection begins moving beyond its initial entry site.
This protection is extremely important. It helps prevent the virus from causing pneumonia, organ complications, and other severe outcomes. However, circulating immunity may not always stop the earliest rounds of viral replication in the nose, particularly when immunity has waned or a new variant partially escapes existing antibodies.
Secretory IgA may help guard the entry point
Mucosal vaccines are intended to generate antibodies such as secretory immunoglobulin A, commonly called IgA. This antibody can sit in mucus and on mucosal surfaces, where it may bind viral particles before they establish a larger infection.
A successful intranasal COVID vaccine could also produce tissue-resident memory T cells. Unlike immune cells circulating through the bloodstream, these specialized cells remain stationed in respiratory tissues, ready to respond locally instead of commuting to the scene after trouble has already started.
Research continues to show that airway IgA and tissue-based immune responses are important targets for next-generation vaccines, while conventional systemic vaccination does not reliably generate strong or durable respiratory mucosal immunity in every person.
Could a nasal vaccine reduce transmission?
That is one of the biggest hopes, but it remains a question that clinical trials must answer. If a vaccine reduces viral replication in the upper airway, it could theoretically lower the amount of virus an infected person sheds and shorten the contagious period.
Reducing infection and transmission is much harder than preventing hospitalization. A nasal vaccine must act quickly, work against evolving variants, and maintain sufficient immunity despite mucus, nasal enzymes, and the respiratory tract’s natural cleaning machinery.
For this reason, “potential to reduce transmission” should not be translated into “guaranteed sterilizing immunity.” Viruses rarely sign contracts, and SARS-CoV-2 has been particularly enthusiastic about the fine print.
How Intranasal COVID Vaccines Work
Viral-vector vaccines
Many nasal candidates use a harmless or weakened respiratory virus as a delivery vehicle. The vector carries genetic instructions for one or more SARS-CoV-2 antigens into cells lining the airway. Those cells briefly produce the antigen, allowing the immune system to practice recognizing it.
One U.S. candidate, CVXGA1, uses parainfluenza virus type 5 as a vector. A Phase 1 study evaluated intranasal administration in adults and adolescents. The vaccine generated measurable systemic and nasal immune responses, and the findings supported continued clinical development. Larger controlled trials are needed to determine how effectively updated versions prevent infection and disease.
Protein and adjuvanted nasal vaccines
Other candidates deliver purified SARS-CoV-2 proteins, frequently with an adjuvant that signals the immune system to pay closer attention. Protein-based vaccines cannot replicate, but nasal formulations must overcome the challenge of keeping enough antigen on the mucosal surface long enough to generate a meaningful response.
Live-attenuated platforms
A live-attenuated vaccine uses a weakened organism capable of limited replication without causing the disease it is designed to prevent. Because it behaves somewhat like a natural respiratory infection, it may stimulate broad local and systemic immunity.
These platforms require careful safety evaluation. Eligibility may eventually differ for pregnant people, immunocompromised patients, young children, older adults, or people with certain respiratory conditions. Experience with intranasal influenza vaccination demonstrates that nasal vaccines can be practical, but one spray is not automatically suitable for every nose attached to every human.
Prime-and-pull strategies
A particularly promising approach combines an injected vaccine with a later mucosal booster. The injection “primes” systemic immunity, while the nasal dose “pulls” immune cells and antibodies toward the respiratory tract.
This strategy could be practical because much of the population already has immune memory from previous vaccination, infection, or both. Preclinical studies have found that an intramuscular prime followed by an intranasal boost can produce stronger airway IgA and better upper-respiratory protection than an injected vaccine alone. Human trials must determine whether those advantages translate into durable real-world protection.
Prominent Nasal SARS-CoV-2 Vaccine Research
The NIH MPV/S-2P candidate
In 2024, the National Institutes of Health opened a first-in-human Phase 1 trial of MPV/S-2P. The vaccine uses murine pneumonia virus as a vector to deliver a stabilized SARS-CoV-2 spike protein. The vector does not cause disease in humans but naturally targets respiratory epithelial cells.
The study was designed to enroll 60 adults who had previously received at least three mRNA COVID-19 vaccine doses. Participants receive one nasal dose at different dose levels and complete multiple follow-up visits over approximately one year. Researchers measure tolerability, blood antibodies, and immune responses in the nose.
Preclinical primate studies produced both systemic and respiratory mucosal responses, but Phase 1 testing is primarily about safety and immune measurementsnot proof that the vaccine prevents transmission in the general population.
CVXGA and the move toward Phase 2b testing
An updated candidate known as CVXGA50 contains an antigen matched to a more recent SARS-CoV-2 lineage. A registered Phase 2b study is designed to compare its safety and relative effectiveness with an injectable COMIRNATY vaccine. This type of active-comparator trial can help determine whether nasal vaccination offers a measurable advantage rather than merely producing interesting laboratory numbers.
International Phase 3 evidence
Large trials outside the United States have shown that intranasal COVID vaccination is feasible, although results have not produced a single universal success story.
In a randomized Phase 3 study involving more than 30,000 participants, the influenza-vectored dNS1-RBD nasal vaccine was generally well tolerated. Its estimated efficacy against symptomatic Omicron infection was approximately 28%, with considerable statistical uncertainty. The result provided valuable proof that a nasal vaccine can be tested at large scale, while also showing how difficult it is to prevent symptomatic infection during rapidly changing variant waves.
Project NextGen and the U.S. Development Pipeline
The U.S. government created Project NextGen to support vaccines and treatments that improve upon first-generation pandemic tools. Its stated priorities include broader protection, longer-lasting immunity, easier administration, pan-coronavirus coverage, and better control of infection and transmission.
Mucosal vaccines are an important part of this strategy. Government-supported trials can compare different platforms using standardized laboratory tests, clinical endpoints, and study networks. This makes it easier to identify which products deserve larger, more expensive efficacy trials.
The program is exploring more than nasal sprays. Oral vaccines, inhaled aerosols, microneedle patches, non-spike antigens, and multivalent formulations may all contribute to future pandemic preparedness. The eventual winner may be one productor a toolbox in which different vaccines serve different populations.
Potential Benefits of a Nasal COVID Vaccine
- Needle-free administration: A nasal spray may be easier for children, people with needle anxiety, and mass-vaccination programs.
- Local respiratory immunity: The vaccine may generate IgA and tissue-resident immune cells near the infection site.
- Possible reduction in infection: Faster upper-airway responses could limit early viral replication.
- Possible reduction in spread: Lower or shorter viral shedding might reduce transmission, although this must be demonstrated in trials.
- Convenient boosting: Nasal boosters could supplement immunity established by previous injectable vaccines.
- Easier distribution: Some platforms may eventually simplify administration, staffing, or storage.
The FDA’s approval of FluMist for self- or caregiver administration shows that at-home delivery of a properly tested nasal vaccine is technically and operationally possible. It does not mean a future COVID nasal spray will automatically receive the same indication, but it provides a useful regulatory precedent.
The Scientific and Practical Challenges
The nose is built to remove foreign material
Mucus and microscopic cilia continually trap and clear particles. This protects the lungs, but it can also remove vaccine material before the immune system has enough time to study it. Developers must optimize droplet size, spray pattern, dose volume, stability, and adhesion to nasal tissue.
Immune responses are difficult to measure
Blood antibody tests are relatively standardized. Nasal samples are more variable. Results can change depending on collection methods, mucus volume, dilution, timing, recent infection, and laboratory technique.
Researchers must also determine which measurements actually predict protection. A high nasal IgA result looks encouraging, but regulators need evidence connecting that result with fewer infections, lower viral loads, reduced illness, or reduced transmission.
Variants keep changing the target
A vaccine built around one spike sequence may lose effectiveness when new variants accumulate immune-evasive mutations. Developers are therefore testing updated antigens, multiple receptor-binding domains, conserved viral proteins, or combinations of spike and nucleoprotein.
Animal studies suggest that multicomponent nasal vaccines can broaden protection and reduce transmission, but animal challenge experiments cannot replace human efficacy studies. Hamsters are useful research partners; they are not famous for commuting on crowded subways or filling out symptom questionnaires.
Manufacturing must be consistent
Every sprayer must deliver the intended dose. The formulation must remain stable during storage and shipping, and manufacturing must reliably control potency, purity, sterility, and particle characteristics.
Safety depends on the platform
Possible reactions may include temporary nasal congestion, runny nose, sneezing, headache, fatigue, or sore throat. Live-vector products require additional attention to replication, shedding, preexisting immunity to the vector, and use in medically vulnerable groups.
Only adequately controlled trials can establish the real side-effect profile of a specific product. A bottle marketed online as an “immune nasal shield” is not the same thing as a regulated vaccine. The FDA has previously warned companies selling unapproved nasal products with COVID-19 prevention or treatment claims.
Could Nasal Vaccines Replace COVID Shots?
Replacement is possible in some settings, but supplementation may be a more realistic first step. Injectable vaccines have a strong record of protecting against severe disease. A nasal booster could add mucosal immunity without discarding the systemic immune memory already created.
Future schedules might use an injection for the initial series and periodic nasal boosters afterward. Another possibility is that healthy adults receive a nasal product while people at higher risk receive a stronger systemic vaccine, a nasal booster, or both.
The best schedule will depend on clinical outcomes, duration of protection, variant coverage, age, underlying health, vaccine platform, cost, and public acceptance. There is no scientific rule requiring one route of administration to defeat the other in single combat.
Frequently Asked Questions
Is there an FDA-approved nasal spray vaccine for COVID-19?
No. As of July 2026, the FDA has not licensed an intranasal SARS-CoV-2 vaccine in the United States. Available licensed U.S. COVID-19 vaccines are administered by injection.
Are nasal COVID vaccines available elsewhere?
Several countries have authorized mucosal COVID vaccines delivered through the nose or by inhalation. Products, eligibility rules, evidence standards, and authorization status differ by country.
Would a nasal vaccine prevent every infection?
Probably not. The realistic goal is to reduce the likelihood of infection, limit viral replication, shorten illness, reduce transmission, or strengthen protection against severe outcomes. The exact benefits will vary by vaccine and circulating variant.
Can an ordinary nasal spray prevent COVID-19?
No over-the-counter saline, antihistamine, antiseptic, or decongestant spray should be treated as a substitute for an authorized vaccine or evidence-based medical care. Some nasal products are being studied for prevention, but experimental findings do not establish routine clinical effectiveness.
When might a U.S. nasal COVID vaccine become available?
No dependable approval date exists. Candidates must complete clinical trials, demonstrate a favorable benefit-risk profile, establish reliable manufacturing, and undergo FDA review. Promising early data can accelerate development, but it cannot skip those steps.
Experiences Related to Nasal Spray Vaccination
What receiving a future nasal COVID vaccine may feel like
For most people, the most noticeable difference would be the absence of a needle. A recipient would likely sit upright while a clinician positions a prefilled sprayer just inside one nostril. Depending on the device, the dose could be divided between both nostrils. Administration would take only a few seconds.
The process may produce a cool sensation, a medicinal taste at the back of the throat, an immediate desire to sniff, or a brief urge to sneeze. Anyone who has accidentally inhaled swimming-pool water may imagine something dramatic, but modern vaccine sprayers deliver a carefully controlled, small volume. The goal is to coat nasal tissue, not pressure-wash the sinuses.
Recipients may be instructed not to blow their nose immediately after dosing. They might remain at the clinic for a short observation period, particularly during early rollout or when the product is being given within a clinical trial.
The clinical-trial experience is more involved
People participating in an investigational nasal SARS-CoV-2 vaccine study experience considerably more than a quick spray. Screening may include a medical history, physical examination, pregnancy testing when applicable, blood collection, and confirmation of previous COVID vaccination or infection.
After administration, participants typically record symptoms in an electronic diary. Researchers may ask about congestion, runny nose, headache, fever, fatigue, sore throat, coughing, or changes in smell. Volunteers return for blood draws and nasal sampling so investigators can compare systemic antibodies with mucosal IgA and other local immune markers.
Nasal sampling is not always the highlight of the day. Depending on the protocol, researchers may use an absorbent strip, nasal swab, wash, or lining-fluid collection device. It is generally brief, although the eyes may water and dignity may temporarily file for vacation.
The NIH MPV/S-2P Phase 1 protocol, for example, was designed around one nasal dose followed by seven visits over approximately one year. This long follow-up allows researchers to detect delayed safety issues and determine whether mucosal immunity lasts for weeks, months, or longer.
Convenience could change vaccine behavior
A needle-free option may make vaccination less stressful for people with injection anxiety. Parents may find a spray easier than negotiating with a frightened child who has suddenly developed the grip strength of an adult gorilla. Pharmacies, schools, workplaces, and community clinics could potentially administer more doses with less equipment and less medical waste.
At-home administration is also plausible for selected products. FluMist provides a real-world example: after eligibility screening and prescription, it can be shipped for self-administration by eligible adults or caregiver administration to eligible children. A COVID nasal vaccine would require its own studies, instructions, age limits, packaging, storage rules, and safeguards before receiving similar approval.
Not every experience will be effortless
People with severe nasal congestion, recent nasal surgery, frequent nosebleeds, structural abnormalities, or certain chronic respiratory conditions may need additional guidance. A dose delivered while the nose is heavily blocked might not distribute as intended. Live-vector vaccines may also carry restrictions for people with weakened immune systems.
Some recipients will still prefer an injection. Others may dislike nasal sensations or worry about sneezing out the dose. Clear instructions and well-designed devices will therefore matter almost as much as the biology.
The ideal experience would be simple: confirm eligibility, administer the spray correctly, experience only mild and temporary effects, and gain meaningful protection where the virus first arrives. Whether current candidates can consistently deliver that experience is exactly what ongoing clinical trials are trying to discover.
Conclusion: A Promising Front Door Defense That Still Needs Proof
The nasal spray vaccine for SARS-CoV-2 represents one of the most compelling directions in next-generation COVID-19 prevention. By targeting mucosal immunity in the nose and respiratory tract, these vaccines may address a weakness of injected vaccines: limited ability to stop the earliest stages of upper-airway infection.
Early human studies, international trials, and animal research provide reasons for optimism. Researchers have demonstrated that nasal vaccination can generate local IgA, systemic antibodies, and respiratory tissue immunity. Some candidates have progressed from laboratory experiments into Phase 1 and Phase 2b development.
Important questions remain. Scientists must establish durable protection, meaningful effectiveness against changing variants, consistent manufacturing, appropriate eligibility rules, and convincing evidence of reduced infection or transmission.
For now, nasal SARS-CoV-2 vaccines should be viewed as promising investigational technologynot as an approved replacement for currently available COVID vaccination in the United States. The nose may eventually become the immune system’s best-defended entrance, but science still has a few locks to install.